Voronoi Seeks Phase 1 Approval for Non-Small Cell Lung Cancer Treatment
Voronoi Applies for Phase 1 Clinical Trial Approval for NSCLC Treatment The innovative drug design company Voronoi, led by CEO Kim Dae-kwon and Kim Hyeon-tae, has submitted an application for approval of the phase 1 clinical trial design (IND) for VRN11, a potential treatment for non-small cell lung cancer (NSCLC), to the Food and Drug […]
